Abbott Hits Hospira With Patent Suit Over Zemplar

Law360, New York (July 22, 2011, 4:30 PM EDT) -- Abbott Laboratories slapped Hospira Inc. with a lawsuit Thursday in Delaware federal court, claiming that Hospira infringed two patents by trying to tap into the market for paricalcitol, which Abbott markets as the kidney disease treatment Zemplar.

The plaintiff claims Lake Forest, Ill.-based Hospira infringed the patents-in-suit when it filed New Drug Application No. 201-657 pursuant to Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, seeking a green light from the U.S. Food and Drug Administration for three formulations of injectable paricalcitol drug products...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.